{"id":8413,"date":"2025-08-20T13:43:45","date_gmt":"2025-08-20T10:43:45","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8413"},"modified":"2025-08-20T13:43:45","modified_gmt":"2025-08-20T10:43:45","slug":"2025-acc-aha-hypertension-guideline-gp-practical-summary","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/2025-acc-aha-hypertension-guideline-gp-practical-summary\/","title":{"rendered":"2025 ACC\/AHA Hypertension Guideline \u2014 GP Practical Summary"},"content":{"rendered":"
2025 ACC\/AHA Hypertension Guideline \u2014 GP Practical Summary<\/div>\n
<\/div>\n
Source & Date: American Heart Association \/ American College of Cardiology Hypertension Guideline (May\u2013Aug 2025).<\/div>\n
Published in: JACC, Circulation, Hypertension (DOI: 10.1016\/j.jacc.2025.05.007).<\/div>\n
<\/div>\n
1. BP Classification (Office)<\/div>\n
1. Normal: <120\/<80 mmHg<\/span><\/div>\n
2. Elevated: 120\u2013129\/<80 mmHg<\/span><\/div>\n
3. Stage 1 HTN: 130\u2013139\/80\u201389 mmHg<\/span><\/div>\n
4. Stage 2 HTN: \u2265140\/\u226590 mmHg<\/span><\/div>\n
<\/div>\n
\u2022 Always classify into the higher category if SBP\/DBP differ.<\/span><\/div>\n
\u2022 Confirm with \u22652 readings per visit on \u22652 occasions.<\/span><\/div>\n
2. Accurate BP Measurement<\/div>\n
5. Use validated devices (validatebp.org); correct cuff size.<\/span><\/div>\n
6. Avoid caffeine, exercise, smoking 30 min before.<\/span><\/div>\n
7. Average \u22652 readings per visit; repeat at \u22652 visits.<\/span><\/div>\n
8. Re-train staff every 6\u201312 months.<\/span><\/div>\n
3. Out-of-Office Monitoring<\/div>\n
9. ABPM\/HBPM recommended for diagnosis, titration, white-coat & masked HTN.<\/span><\/div>\n
10. Thresholds:<\/span><\/div>\n
<\/div>\n
\u2022 HBPM \u2265130\/80<\/span><\/div>\n
\u2022 Daytime ABPM \u2265130\/80<\/span><\/div>\n
\u2022 Night ABPM \u2265110\/65<\/span><\/div>\n
\u2022 24h ABPM \u2265125\/75<\/span><\/div>\n
4. When to Start Medications<\/div>\n
11. High risk (CVD, CKD, diabetes, 10y risk \u22657.5%): \u2265130\/80.<\/span><\/div>\n
12. Lower risk (<7.5%): \u2265140\/90; or \u2265130\/80 after 3\u20136 months lifestyle.<\/span><\/div>\n
13. Stage 2 HTN: start 2 first-line drugs, ideally in single-pill combo.<\/span><\/div>\n
5. Treatment Targets<\/div>\n
14. General goal: <130\/80 mmHg for most adults.<\/span><\/div>\n
15. Exceptions: frail elderly, institutionalized, pregnancy (specific targets).<\/span><\/div>\n
6. Lifestyle Interventions<\/div>\n
16. Weight loss: Aim BMI 18.5\u201324.9; \u22655% loss if overweight.<\/span><\/div>\n
17. Diet: DASH; Na <2.3 g\/day (ideal <1.5 g); \u2191 K\u207a if safe.<\/span><\/div>\n
18. Exercise: \u2265150 min\/week moderate aerobic + resistance \u22652\/week.<\/span><\/div>\n
19. Alcohol: \u22641 drink\/day (women), \u22642 (men).<\/span><\/div>\n
20. Stress: yoga, meditation, breathing techniques.<\/span><\/div>\n
7. Special Populations<\/div>\n
<\/div>\n
Stroke \/ ICH<\/div>\n
21. ICH: SBP 150\u2013220 \u2192 lower to 130\u2013140 for 7 days; avoid <130 early.<\/div>\n
22. Ischemic stroke with thrombolysis: <185\/110 before, then <180\/105 for 24h.<\/div>\n
23. No reperfusion & BP \u2265220\/120: reduce by ~15% in 24h.<\/div>\n
24. Secondary prevention: target <130\/80; use thiazide, ACEi, or ARB.<\/div>\n
<\/div>\n
CKD<\/div>\n
25. Target <130\/80; ACEi\/ARB first-line if albuminuria \u226530 mg\/g.<\/div>\n
26. Avoid ACEi + ARB combo.<\/div>\n
<\/div>\n
Diabetes<\/div>\n
27. Target <130\/80; ACEi\/ARB preferred with albuminuria.<\/div>\n
<\/div>\n
Pregnancy<\/div>\n
28. Acute severe HTN (\u2265160\/110): treat within 30\u201360 min, with gradual reduction over ~30 min. First-line: IV labetalol, oral nifedipine, or methyldopa.<\/div>\n
29. Chronic HTN: target <140\/90.<\/div>\n
30. Safe drugs: labetalol, nifedipine, methyldopa.<\/div>\n
\u2022 Avoid ACEi, ARB, direct renin inhibitors, mineralocorticoid antagonists, and atenolol (linked to fetal growth restriction & neonatal complications).<\/span><\/div>\n
<\/div>\n
OSA<\/div>\n
31. Screen in resistant HTN or suggestive symptoms.<\/div>\n
32. CPAP + weight loss modestly improve BP.<\/div>\n
<\/div>\n
HIV<\/div>\n
33. Standard treatment; monitor drug\u2013drug interactions (esp. with CCBs).<\/div>\n
<\/div>\n
Transplant<\/div>\n
34. First-line: amlodipine; avoid verapamil\/diltiazem with calcineurin inhibitors.<\/div>\n
8. Resistant Hypertension<\/div>\n
35. Defined as uncontrolled BP on \u22653 drugs (incl. diuretic) or controlled on \u22654.<\/span><\/div>\n
36. Add spironolactone if eGFR \u226545; alternatives: amiloride, \u03b2-blocker, \u03b1-blocker, clonidine.<\/span><\/div>\n
37. Exclude secondary causes; remove interfering drugs.<\/span><\/div>\n
38. Renal Denervation (RDN) \u2013 Class IIb option if uncontrolled.<\/span><\/div>\n
9. What\u2019s New in 2025<\/div>\n
39. \u201cHypertensive urgency\u201d renamed \u201cSevere Hypertension\u201d (no organ damage).<\/span><\/div>\n
40. Primary aldosteronism screening expanded (all resistant HTN).<\/span><\/div>\n
41. Potassium-based salt substitutes broadly recommended.<\/span><\/div>\n
42. Avoid lowering SBP <140 in first 24\u201372h post-reperfusion stroke.<\/span><\/div>\n
43. Emphasis on community-based screening & team-based care.<\/span><\/div>\n
10. Hypertensive Emergencies (BP >180\/120 + organ damage)<\/div>\n
\u2022 ICU admission; titratable IV drugs (nicardipine, clevidipine, labetalol, esmolol, hydralazine, enalaprilat).<\/span><\/div>\n
\u2022 Nitrates only for ACS or pulmonary edema.<\/span><\/div>\n
\u2022 If IV unavailable: oral captopril (preferred; rapid under tongue or swallowed).<\/span><\/div>\n
\u2022 Oral nifedipine only in preeclampsia\/eclampsia.<\/span><\/div>\n
\u2022 Evidence note: Sublingual captopril reduces SBP & MAP more rapidly than oral in first 30 min, but effect is similar at 60 min.<\/span><\/div>\n
\u2022 Target: reduce \u226425% in 1h, then <160\/100 in 2\u20136h, then 130\u2013140\/80\u201390 in 24\u201348h.<\/span><\/div>\n
11. Other Clinical Notes<\/div>\n
\u2022 Orthostatic Hypotension: Check baseline & after intensification; not a reason to avoid intensive BP control.<\/span><\/div>\n
\u2022 Sexual dysfunction: Diuretics & \u03b2-blockers worsen it; ARBs safest. PDE-5 inhibitors safe (not with nitrates).<\/span><\/div>\n
\u2022 Perioperative BP: Continue most drugs; stop ACEi\/ARB 24h before major surgery; defer elective surgery if \u2265180\/110.<\/span><\/div>\n
12. GP Quick Checklist<\/div>\n
<\/div>\n
\u2610 Confirm diagnosis with ABPM\/HBPM.<\/div>\n
\u2610 Classify & stage BP.<\/div>\n
\u2610 Assess 10y risk (PREVENT tool).<\/div>\n
\u2610 Initiate lifestyle \u00b1 drugs per stage\/risk.<\/div>\n
\u2610 Use single-pill combos where possible.<\/div>\n
\u2610 Monitor monthly until goal achieved.<\/div>\n
\u2610 Screen for secondary causes if resistant\/atypical.<\/div>\n
<\/div>\n
Key Takeaway:<\/div>\n
For most adults, target <130\/80 mmHg using validated BP methods, lifestyle change, risk-based thresholds for treatment, and single-pill drug combinations.<\/div>\n
Special attention: treat pregnancy-related severe hypertension within 30\u201360 minutes, avoid atenolol, use safe drugs, and apply new terminology (Severe Hypertension).<\/div>\n
Resistant hypertension requires structured evaluation and, in select cases, renal denervation.<\/div>\n","protected":false},"excerpt":{"rendered":"

2025 ACC\/AHA Hypertension Guideline \u2014 GP Practical Summary Source & Date: American Heart Association \/ American College of Cardiology Hypertension Guideline (May\u2013Aug 2025). Published in: JACC, Circulation, Hypertension (DOI: 10.1016\/j.jacc.2025.05.007). 1. BP Classification (Office) 1. Normal: <120\/<80 mmHg 2. Elevated: 120\u2013129\/<80 mmHg 3. Stage 1 HTN: 130\u2013139\/80\u201389 mmHg 4. Stage 2 HTN: \u2265140\/\u226590 mmHg \u2022 […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8413","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8413"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8413\/revisions"}],"predecessor-version":[{"id":8414,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8413\/revisions\/8414"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}